Treatment of multiple myeloma

THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST.

1889 • 4,920 citations

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

1999 • 2,565 citations

Thalidomide is an inhibitor of angiogenesis.

1994 • 2,460 citations

A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA

2013 • 2,176 citations

High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma

2003 • 1,759 citations

The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma

2003 • 1,491 citations

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1999 • 1,447 citations

Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma

1999 • 1,260 citations

The Systemic Amyloidoses

1997 • 1,174 citations

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1996 • 1,091 citations

Multiple myeloma: evolving genetic events and host interactions

2002 • 815 citations

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

2002 • 812 citations

Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process

1998 • 761 citations

Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents

1984 • 667 citations

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

2002 • 655 citations

Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients

2003 • 622 citations

Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma

2002 • 579 citations

Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma

1997 • 576 citations

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341

2003 • 572 citations

Graft-versus-myeloma effect: proof of principle

1996 • 565 citations

Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial

2002 • 562 citations

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

2001 • 553 citations

Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma

2002 • 531 citations

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

2001 • 529 citations

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

2001 • 525 citations

HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA

1983 • 515 citations

Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

2001 • 512 citations

Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens

1969 • 512 citations

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy

2001 • 497 citations

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials

1998 • 486 citations

Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients

1995 • 459 citations

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

2002 • 431 citations

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.

1998 • 429 citations

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

2003 • 421 citations

Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities

1995 • 418 citations

The Treatment of Multiple Myeloma

1994 • 409 citations

Vertebral Compression Fractures: Pain Reduction and Improvement in Functional Mobility after Percutaneous Polymethylmethacrylate Vertebroplasty—Retrospective Report of 245 Cases

2003 • 398 citations

Kyphoplasty in the Treatment of Osteolytic Vertebral Compression Fractures as a Result of Multiple Myeloma

2002 • 397 citations

Hypodiploidy is a major prognostic factor in multiple myeloma

2001 • 394 citations

Allogeneic Bone Marrow Transplantation in Multiple Myeloma

1991 • 389 citations

Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction Chemotherapy

1990 • 389 citations

Multiple Myeloma

1997 • 389 citations

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

2001 • 385 citations

Treatment for Multiple Myeloma

1969 • 377 citations

Solitary plasmacytoma of bone and asymptomatic multiple myeloma

2000 • 370 citations

High-dose melphalan with autologous bone marrow transplantation for multiple myeloma

1986 • 336 citations

Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities

2000 • 333 citations

Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]

1993 • 321 citations

Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study

2000 • 317 citations

Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy

2001 • 314 citations

Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies

2002 • 312 citations

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

2002 • 309 citations

Results of autologous stem cell transplant in multiple myeloma patients with renal failure

2001 • 300 citations

Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma

1995 • 275 citations

Whole-body (18)F-FDG PET identifies high-risk myeloma.

2002 • 271 citations

High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma

1987 • 270 citations

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

2002 • 260 citations

High-Dose Glucocorticoid Treatment of Resistant Myeloma

1986 • 251 citations

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

2002 • 246 citations

Age Is Not a Prognostic Variable With Autotransplants for Multiple Myeloma

1999 • 242 citations

Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years

2001 • 232 citations

High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.

1994 • 223 citations

Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies

2003 • 208 citations

14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.

1999 • 206 citations

Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization.

1995 • 206 citations

Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial

2001 • 201 citations

Genes encoding tumor-specific antigens are expressed in human myeloma cells

1999 • 201 citations

High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

2001 • 196 citations

Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality

2002 • 196 citations

Improved Outcome of Allogeneic Transplantation in High-Risk Multiple Myeloma Patients After Nonmyeloablative Conditioning

2002 • 186 citations

Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support

1992 • 177 citations

A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up results

1998 • 174 citations

Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease

2001 • 172 citations

High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants

1994 • 172 citations

Thalidomide for previously untreated indolent or smoldering multiple myeloma

2001 • 171 citations

DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma

2003 • 170 citations

Interferon-α treatment in multiple myeloma: Meta-analysis of 30 randomised trials among 3948 patients

2000 • 168 citations

Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma

1996 • 164 citations

The Proliferative Potential of Myeloma Plasma Cells Manifest in the SCID-hu Host

1999 • 164 citations

Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma Patients

1999 • 163 citations

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II

2002 • 159 citations

Mobilization of CD34⁺ cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen

2003 • 158 citations

Autotransplants in multiple myeloma: what have we learned?

1996 • 157 citations

Tumor lysate–specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy

2002 • 152 citations

Intensive combined therapy for previously untreated aggressive myeloma

1992 • 151 citations

Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy

1999 • 150 citations

Downstream effectors of oncogenic ras in multiple myeloma cells

2003 • 149 citations

Clinical activity of arsenic trioxide for the treatment of multiple myeloma

2002 • 148 citations

Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support

1992 • 143 citations

High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients

1993 • 138 citations

Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant

2004 • 138 citations

Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma

2003 • 135 citations

Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression

2003 • 134 citations

Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells

2001 • 133 citations

Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806).

1962 • 127 citations

Prognostic features of asymptomatic multiple myeloma

1997 • 124 citations

The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells

2000 • 122 citations

Oligoclonal Protein Bands and Ig Isotype Switching in Multiple Myeloma Treated With High-Dose Therapy and Hematopoietic Cell Transplantation

1998 • 121 citations

Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

2000 • 120 citations

High-dose melphalan with autologous bone marrow transplantation for multiple myeloma

1986 • 119 citations

Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies

1995 • 117 citations

Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival

2003 • 115 citations

Current status of clinical trials of farnesyltransferase inhibitors

2001 • 114 citations

Cellular DNA content as a marker of human multiple myeloma

1980 • 113 citations

Anti‐myeloma activity of pamidronate in vivo

1998 • 109 citations

Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal [see comments]

1995 • 105 citations

Negative regulation of erythroblast maturation by Fas-L+/TRAIL+ highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma

2002 • 105 citations

Optimizing dendritic cell‐based immunotherapy in multiple myeloma

2002 • 103 citations

Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning

2003 • 95 citations

Thalidomide in the management of multiple myeloma

2001 • 93 citations

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: An evidence-based review

2003 • 92 citations

Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers

1997 • 78 citations

European Group for Blood and Marrow Transplantation Registry studies in multiple Myeloma

2001 • 65 citations

Detection of malignant bone marrow involvement with dynamic contrast-enhanced magnetic resonance imaging

2002 • 63 citations

Treatment of AL-Amyloidosis with Dexamethasone Plus Alpha Interferon

1997 • 62 citations

Thalidomide in the management of multiple myeloma

2001 • 54 citations

Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture?

2002 • 51 citations

A Predictive Model of Varicella-Zoster Virus Infection after Autologous Peripheral Blood Progenitor Cell Transplantation

2001 • 50 citations

Randomized trial experience of the Intergroupe Francophone du Myélome

2001 • 50 citations

Allogeneic hematopoietic cell transplantation for multiple myeloma

2001 • 48 citations

Targeted therapy for multiple myeloma

2001 • 48 citations

Low-dose thalidomide in myeloma: Efficacy and biologic significance

2002 • 38 citations

Arsenic Trioxide

2001 • 36 citations

Low-dose thalidomide in myeloma: Efficacy and biologic significance

2002 • 36 citations

Advances in the biology and treatment of myeloma bone disease

2002 • 34 citations

Advances in the biology and treatment of myeloma bone disease

2002 • 30 citations

Moving disease biology from the laboratory to the clinic

2002 • 21 citations

Salvage Therapy for Multiple Myeloma: The University of Arkansas Experience

1994 • 17 citations

Moving disease biology from the laboratory to the clinic

2002 • 17 citations

Some early phase II trials in previously untreated multiple myeloma: The royal marsden experience

2001 • 11 citations

Gene Expression Profiling after Short Term In-vivo Treatment Identifies Potential Mechanisms of Action of Current Drugs Used To Treat Multiple Myeloma

2002 • 8 citations